Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Modern cancer treatment with PARP inhibitors

Lookup NU author(s): Tomasz Zaremba, Rafal Zur

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Poly(ADP-ribose) polymerase-1 is a DNA-binding enzyme involved in DNA repair. Poly(ADP-ribose) polymerase inhibitors are a growing class of new agents, currently evaluated in clinical trials (phase 0-2) as standard chemotherapy and radiotherapy sensitizers and non-combinational single agents. Poly(ADP-ribose) polymerase inhibitors have been shown to enhance the antitumor activity of DNA-methylating agents, ionizing radiation, and topoisomerase poisons. They are also emerging as an exciting new treatment for familial breast and ovarian cancers by selective killing of cells with homozygous defects in the breast cancer susceptibility genes, BRCA1 and BRCA2. This paper explains the role of poly(ADP-ribose) polymerase in DNA repair in relation to cancer and discusses published results of preclinical and early clinical studies on poly(ADP-ribose) polymerase inhibitors.

Publication metadata

Author(s): Zaremba T, Zur R

Publication type: Article

Publication status: Published

Journal: Cancer and Chemotherapy Reviews

Year: 2009

Volume: 4

Issue: 1

Pages: 27-34

Print publication date: 01/01/2009

ISSN (print): 1885-740X

ISSN (electronic):

Publisher: Permanyer Publications

Share